CAMBRIDGE, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today announced positive results from pooled data from three open-label, multicenter, randomized Phase III trials of ferumoxytol as an intravenous iron replacement therapeutic. The data is being presented today at approximately 6:00 pm ET as a poster at the 49th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia. The poster is available on the Company’s web site at www.amagpharma.com.
